Sentynl Therapeutics, Inc. v. U.S. Specialty Insurance Company, 3:19-cv-01667

Background

Sentynl Therapeutics marketed two FDA‑classified opioid products during the policy period: Levorphanol and Abstral.
US Specialty Insurance Co. (USSI) issued a Directors & Officers/Organization liability policy (1/31/2018–1/31/2019) that excludes "Loss in connection with a Claim arising out of ... any goods or products ... marketed [by] the Insured Organization."
The U.S. Attorney’s Office Opioid Task Force served subpoenas requesting documents about Sentynl’s promotion, marketing, distribution, and related payments tied largely to Levorphanol (and later Abstral).
Sentynl sought coverage for defense costs; USSI denied coverage, invoking the Goods and Products Exclusion.
Sentynl sued for breach of contract, bad faith, and declaratory relief; both parties moved for summary judgment on whether the exclusion barred coverage for the Investigation.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Scope of “arising out of” in a products/goods exclusion	"Arising out of" should be read narrowly—limited to product‑liability style claims; otherwise exclusion would eliminate meaningful insurance for a product company	Under California law the phrase is broad: "originating from, growing out of, flowing from" and is not limited to defective‑product theories	Court: "Arising out of" is broad and unambiguous; not limited to products‑liability theories (adopts broad construction)
Whether the Opioid Task Force Investigation is a Claim "arising out of" Sentynl's products	The Investigation is not a products claim and seeks coverage for defense costs	The Investigation targets allegedly unlawful marketing/distribution tied to the opioids’ addictive properties and thus originates from Sentynl’s products	Court: Undisputed facts show the Investigation arises out of Sentynl’s opioid products; exclusion applies; USSI entitled to summary judgment
Effect of Electronic Purification and concern that exclusion would "eliminate practically all meaningful insurance"	The exclusion should be limited by precedent (Electronic Purification) to avoid sweeping away coverage for routine business activities	The Policy’s caption and the unambiguous phrase "arising out of" control; activities unrelated in origin to products remain covered	Court: Electronic Purification is distinguishable; difference between acts merely related to doing business and acts that originate from the products; Sentynl’s activity here originates from its opioid products

Key Cases Cited

Fibreboard Corp. v. Hartford Accident & Indemnity Co., 16 Cal. App. 4th 492 (1993) (defines the "core factual nucleus" test for "arising out of")
Continental Cas. Co. v. City of Richmond, 763 F.2d 1076 (9th Cir. 1985) (construed "arising out of" as unambiguous and broadly phrased)
Travelers Prop. Cas. Co. of Am. v. Actavis, Inc., 16 Cal. App. 5th 1026 (2017) (marketing‑based opioid claims found to "arise out of" the opioids even without defect allegations)
Ins. Co. of N. Am. v. Electronic Purification Co., 67 Cal. 2d 679 (1967) (interpreting scope of a "Products Hazard" exclusion where caption and text limit application)
MacKinnon v. Truck Ins. Exchange, 31 Cal. 4th 635 (2003) (principles of insurance contract interpretation under California law)
Fireman’s Fund Ins. Cos. v. Atlantic Richfield Co., 94 Cal. App. 4th 842 (2001) ("arising out of" requires more than but‑for causation)
Atlantic Mutual Ins. v. J. Lamb, Inc., 100 Cal. App. 4th 1017 (2002) (insurer must establish undisputed facts that eliminate potential for liability to avoid defense duty)